PetMed Express, Inc. (NASDAQ: PETS) extended its shareholder rights plan, a defensive “poison pill,” by moving the expiration date from December 2, 2025 to December 2, 2026. The board approved the amendment unanimously on November 26, 2025, and all other terms of the plan remain unchanged.
The extension comes as the company reports a sharp decline in revenue and a net loss. In the third quarter of fiscal 2025, net sales fell to $53.0 million from $65.3 million a year earlier, and the company posted a net loss of $0.03 per share, missing analyst expectations. Preliminary full‑year guidance for fiscal 2025 projects net sales between $231.6 million and $233.6 million, down from $281.1 million in fiscal 2024. The company has also faced reporting delays and a Nasdaq non‑compliance notice for a late filing of its September 30, 2025 10‑Q.
The board’s decision to extend the rights plan is aimed at protecting shareholders from potential takeover attempts that could arise as certain investors accumulate significant stakes. By keeping the poison pill in place for an additional year, the company signals that it believes its shares are undervalued and that any controlling acquisition would need to offer a fair premium to all shareholders. The move also reflects management’s concern that the company’s weakened financial position could make it an attractive target for hostile bids.
The extension does not alter the company’s financial trajectory but adds a layer of defensive protection. Investors now face a higher barrier to acquiring a controlling interest, which could influence future takeover activity and shareholder negotiations. The company’s ongoing cost‑control initiatives and operational efficiencies—such as a 0.9 % increase in gross margin to 28.1 % and a rise in adjusted EBITDA to $2.0 million in Q3 fiscal 2025—are part of a broader transformation strategy aimed at stabilizing earnings while the rights plan remains active.
While the market has not yet reacted strongly to the rights‑plan extension, the broader context of declining revenue, net losses, and regulatory compliance challenges continues to weigh on investor sentiment. The company’s defensive posture may reassure shareholders that management is actively safeguarding their interests, but it also underscores the underlying financial headwinds that could make PetMed Express vulnerable to future takeover attempts if the company’s performance does not improve.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.